DOCSLIB.ORG

Antifungals, Topical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antifungals, Topical EFFECTIVE 1/1/2021 Drug and Biologic Coverage Policy Effective Date ............................................ 1/1/2021 Next Review Date… ..................................... 1/1/2022 Coverage Policy Number ................................ P0046 Antifungals, Topical Table of Contents Related Coverage Resources Overview ...................................................................1 Coverage Policy Statement ......................................1 FDA Indication Criteria ..............................................2 Other Uses with Supportive Evidence Criteria .........3 Specific Additional Criteria ........................................3 Preferred Product Requirement Criteria ...................3 Conditions Not Covered............................................4 Background ...............................................................4 References ...............................................................5 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Overview This policy supports medical necessity review for topical antifungals. Coverage Policy Statement Topical antifungal products (Ertaczo® cream, Exelderm® cream/solution, Extina® foam, Jublia® topical solution, Kerydin® topical solution, Loprox® cream/shampoo, Luzu™ cream, miconazole/zinc oxide/white petrolatum ointment, Oxistat® cream/lotion, Penlac® nail lacquer solution, Vusion® ointment, Xolegel™ gel) are medically necessary when the following are met: 1. Criteria associated with FDA Indications 2. Criteria associated with Other Uses with Supportive Evidence 3. Specific Additional Criteria [when part of Cigna managed drug list or plan requirements] 4. Preferred Product Requirement Criteria [when part of Cigna managed drug list or plan requirements] Page 1 of 6 Coverage Policy Number: P0046 EFFECTIVE 1/1/2021 When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy. Approval duration is 12 months unless otherwise stated. Note: Receipt of sample product does not satisfy any criteria requirements for coverage. Documentation: When documentation is required, the prescriber must provide written documentation supporting the trials of these other agents. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts Refer to each criteria section below. FDA Indication Criteria Non-Covered FDA Indication Criteria Product Ertaczo BOTH of the following: cream, 2% ● Individual is 12 years of age and older ● Documented diagnosis of interdigital pedis Exelderm cream, BOTH of the following: 1.0% ● Individual is 18 years of age and older ● Documented diagnosis of tinea corporis, tinea cruris, tinea pedis, or tinea versicolor Exelderm solution, BOTH of the following: 1.0% ● Individual is 18 years of age and older ● Documented diagnosis of tinea corporis, tinea cruris, tinea pedis, or tinea versicolor Extina BOTH of the following: foam, 2% ● Individual is 12 years of age and older ● Documented diagnosis of seborrheic dermatitis Jublia BOTH of the following: topical solution, ● Individual is 18 years of age and older 10% ● Documented diagnosis of onychomycosis of the toenail(s) Kerydin BOTH of the following: topical solution, 5% ● Individual is 6 years of age and older ● Documented diagnosis of onychomycosis of the toenail(s) Loprox cream, None. 0.77% Loprox BOTH of the following: shampoo, 1% ● Individual is 18 years of age and older ● Documented diagnosis of seborrheic dermatitis Luzu ● Documented diagnosis of tinea corporis, tinea cruris, tinea pedis, or tinea versicolor cream, 1% miconazole/zinc ALL of the following: oxide/white ● Pediatric individual 4 weeks of age and older petrolatum ● Documented diagnosis of diaper dermatitis ointment, 0.25%- ● Presence of candida infection 15%-81.35% The approval will be limited to a (7) day supply. Oxistat None. cream, 1% Oxistat None. lotion, 1% Penlac ● Documented diagnosis of onychomycosis of the fingernail(s) or toenail(s) Page 2 of 6 Coverage Policy Number: P0046 EFFECTIVE 1/1/2021 Non-Covered FDA Indication Criteria Product nail lacquer solution, 8% Vusion ALL of the following: ointment, 0.25%- ● Pediatric individual 4 weeks of age and older 15%-81.35% ● Documented diagnosis of diaper dermatitis ● Presence of candida infection The approval will be limited to a (7) day supply. Xolegel gel, 2% None. Other Uses with Supportive Evidence Criteria None. Specific Additional Criteria None. Preferred Product Requirement Criteria Coverage varies across plans. Refer to the customer’s benefit plan document for coverage details. Where coverage requires the use of preferred products, the following criteria apply: Approve for an individual when there is documentation of ONE of the following: • The individual has had inadequate efficacy OR contraindication according to FDA label OR significant intolerance to ALL of covered alternatives according to the table below OR • The individual is not a candidate for ALL covered alternatives according to the table below due to being subject to a warning per the prescribing information (labeling), having a disease characteristic, individual clinical factor[s], or other attributes/conditions or is unable to administer and requires this dosage formulation Employer Group Non-Covered Products and Preferred Covered Alternatives by Drug List: Non-Covered Standard / Value / Cigna Total Legacy Product Performance Advantage Savings Ertaczo ALL of the following: clotrimazole cream, econazole cream, naftifine cream (sertaconazole nitrate) cream, 2% Exelderm cream, ALL of the following: ciclopirox cream/lotion, econazole cream, ketoconazole cream, 1.0% naftifine cream, oxiconazole cream Exelderm solution, ALL of the following: ciclopirox cream/lotion, econazole cream, ketoconazole 1.0% cream/shampoo, naftifine cream, oxiconazole cream Extina BOTH of the following: ciclopirox shampoo, sulfacetamide sodium shampoo foam, 2% Jublia ALL of the following: ciclopirox nail lacquer solution, itraconazole capsules, terbinafine topical solution, tablets 10% Kerydin ALL of the following: ciclopirox nail lacquer solution, itraconazole capsules, terbinafine topical solution, 5% tablets Page 3 of 6 Coverage Policy Number: P0046 EFFECTIVE 1/1/2021 Non-Covered Standard / Value / Cigna Total Legacy Product Performance Advantage Savings Loprox cream, FOUR of the following: clotrimazole cream, econazole cream, ketoconazole cream, 0.77% naftifine cream, oxiconazole cream Loprox BOTH of the following: ketoconazole foam, sulfacetamide sodium shampoo shampoo, 1% Luzu ALL of the following: ciclopirox cream/lotion, econazole cream, ketoconazole cream, cream, 1% naftifine cream, oxiconazole cream miconazole/zinc None. oxide/white petrolatum ointment, 0.25%- 15%-81.35% Oxistat BOTH of the following: cream, 1% ● (1) generic formulation of Oxistat 1% cream ● ALL of the following: clotrimazole cream, econazole cream, ketoconazole cream, naftifine cream Oxistat BOTH of the following: lotion, 1% ● Inability to use oxiconazole 1% cream ● ALL of the following: clotrimazole cream, econazole cream, ketoconazole cream, naftifine cream Penlac BOTH of the following: itraconazole capsules, terbinafine tablets nail lacquer solution, 8% Vusion None. ointment, 0.25%- 15%-81.35% Xolegel gel, 2% FOUR formulary topical products from the following: naftifine cream/gel, econazole cream, ketoconazole cream/foam, oxiconazole cream, ciclopirox cream/gel Individual and Family Plan Covered Alternatives: Non-Covered Covered Alternative(s) Product Jublia ALL of the following: ciclopirox nail
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Evaluation of the Efficacy and Safety of Tavaborole Topical Solution, 5%, In
    Journal of Dermatological Treatment ISSN: 0954-6634 (Print) 1471-1753 (Online) Journal homepage: http://www.tandfonline.com/loi/ijdt20 Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich To cite this article: Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich (2017): Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2017.1329510 To link to this article: http://dx.doi.org/10.1080/09546634.2017.1329510 Accepted author version posted online: 18 May 2017. Published online: 30 May 2017. Submit your article to this journal Article views: 41 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ijdt20 Download by: [Oregon Health & Science University Library] Date: 27 September 2017, At: 13:42 JOURNAL OF DERMATOLOGICAL TREATMENT, 2017 https://doi.org/10.1080/09546634.2017.1329510 ORIGINAL ARTICLE Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K.
    [Show full text]
  • BRAND NAME COMPOSITION Packing Unit BRAND NAME
    BRAND NAME COMPOSITION Packing Unit DOIN-20 SOFT GEL CAP ISOTRETINOIN 20 MG SOFT GEL CAPS 10X1X10 BLISTER FENOGRAS 120 TAB FEXOFENADINE 120MG TABS 10X10 ALU ITRACHEM 100 CAP ITRACONAZOLE 100 MG CAPSULES 10X1X4 STRIP ITRACHEM 200 CAP ITRACONAZOLE 200 MG CAPSULES 10X1X4 STRIP KESHGAIN TABS BIOTIN10MG TABLETS(HAIR GROWTH TABS) 10X1X10 ALU SFLAZA 6 TAB DEFLAZACORT 6MG TABS 10X10 ALU TERBICHEM 250 TAB TERBINAFINE 250MG TABLETS 10X1X7 BLISTER AZYNEX 500 TAB AZITHROMYCIN 500 TAB 10X3 BLISTER BRAND NAME COMPOSITION Packing Unit BEAUTY SOAP WITH ALOE- ALOGLOW SOAP VERA,NEEM,KESAR,SANDAL,TULSI,OLIVE 75GM CARTOON OIL&GLYCERINE KETOLE SOAP KETOCONAZOLE 2% + CERTRIMIDE 0.5% 75GM CARTOON SCABICHEM SOAP PERMETHRIN 5% W/W 75GM CARTOON TRICLOSAN 0.2% + TEA TREE OIL + VIT E 0.4% + ULTRA-SHINE SOAP 75GM CARTOON TITANIUM DIOXIDE SHINE N BEAUTY SOAP NATURAL VIT.E WITH ALOE VERA SOAP 75GM CARTOON BRAND NAME COMPOSITION Packing Unit CALAMINE 15% W/V + ZINC OXIDE 5% W/V + CALACHEM LOTION 100ML CARTOON GLYCERINE 5% W/V CLEANSING LOTION (CETYL ALCOHOL 2.650% CETOCHEM LOTION 100ML CARTOON W/V + STEARYL ALCOHOL 0.260%W/V) CLOBSOL-S LOTION CLOBETASOL + SALICYLIC ACID 3% 50ML CARTOON KETOCONAZOLE 2%W/V + ZINC PYRITHIONE KETOLE-ZPTO SHAMPOO 50ML CARTOON 1%W/W SHAMPOO OCTYL METHOXY CINNAMATE 8% + SWISSGLOW-UV LOTION OXYBENZONE 6.5% + TITANIUM DIOXIDE 0.5% 100ML CARTOON SUNSCREEN LOTION SCABICHEM LOTION PERMETHRIN 5%W/V LOTION 50ML CARTOON BRAND NAME COMPOSITION Packing Unit CLINTOL POWDER CLOTRIMAZOLE 1%W/W POWDER 100GM SHRINK FINNOLE POWDER FLUCONAZOLE 0.5%W/W POWDER
    [Show full text]
  • HMSA ASO Topical Antifungals Jublia (Efinaconazole) Kerydin (Tavaborole
    PA Request Criteria HMSA ASO Topical Antifungals This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 855-762-5207. Please contact CVS/Caremark at 855-240-0543 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Topical Antifungals. Patient Information Patient Name: Patient Phone: - - Patient ID: Patient Group No: Patient DOB: / / Prescribing Physician Physician Name: Physician - - Phone: Physician Fax: - - Physician Address: City, State, Zip: Drug Name (select from list of drugs shown) Jublia (efinaconazole) Kerydin (tavaborole) Oxiconazole Cream Oxistat Cream (oxiconazole) Quantity: ____________ Frequency: __________________ Strength: __________________ Route of Administration: _______________________ Expected Length of Therapy: _____________________ Diagnosis: ICD Code: __________________________________ Comments: _____________________________________________________ ______________________________________________________________________ ______________________________________________________________________ Please check the appropriate answer for each applicable question. 1. Is this a request for oxiconazole cream (Oxistat)? Y N 2. Is the requested drug being prescribed for any of the following: A) tinea corporis, B) tinea Y N cruris, C) tinea pedis, D) tinea versicolor? 3. Is the drug being prescribed for onychomycosis of the toenail(s) due to Trichophyton Y N rubrum and Trichophyton mentagrophytes? 4. Has the diagnosis been confirmed with a fungal diagnostic test (e.g., KOH preparation, Y N fungal culture, or nail biopsy)? I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • Step Therapy Criteria Drug Class Topical Antifungal Agents (Brand Products Only)
    STEP THERAPY CRITERIA DRUG CLASS TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS ONLY) BRAND NAME (generic) ECOZA (econazole) ERTACZO (sertaconazole) EXELDERM (sulconazole nitrate) LOPROX (ciclopirox shampoo) LOTRISONE (clotrimazole/betamethasone) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) OXISTAT (oxiconazole) VUSION (miconazole/zinc oxide/white petrolatum) XOLEGEL (ketoconazole) Antifungal Topical Step Therapy Policy 06-2017 CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). ® Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 4 Status: CVS Caremark Criteria Type: Initial Step Therapy; Post Step Therapy Prior Authorization POLICY FDA-APPROVED INDICATIONS Ecoza Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Common Derm Conditions and Treatments
    4/10/17 Classes of Dermatologic Medications What is that?! Common Dermatologic Conditions and ● Topical Immune Suppressants ● Immune Suppressants How to Treat Them ● Vitamin D Derivatives ● Antibiotics, Antivirals, Antiparasitic Matthew Fox, MD ● Retinoids ● Antimalarials Assistant Professor, Division of Dermatology ● Biologic Agents Dell Medical School, University of Texas at Austin Director of Dermatologic Surgery, Seton Healthcare Family ● Chemotherapeutic agents Learning Objectives Approach to Dermatologic Conditions • Know the clinical subtypes of acne *Know the mechanism and recommended dosing of topical retinoids, oral antibiotics and oral retinoids in the management of acne Acne • Understand the clinical presentation cutaneous dermatophyte infection Infectious diseases of the Skin *Know the classes and recommended dosing of antifungal treatments • Recognize the clinical manifestations of dermatitis Eczema *Know the relative potencies, side effects and indications of topical steroids Psoriasis • Describe the classic clinical findings for psoriasis *Know the mechanism of action and side effects of systemic antipsoriatic medications Sun Damage / Actinic Keratoses • Know the pertinent history and physical exam findings associated with a diagnosis of skin cancer, including the ABCDEs of melanoma Fundamentals Words to the wise… • All medications have side effects If you advise the patients of side effects ahead of time, you are informing the • Always consider drug interactions, patient. including with food and supplements If you did not tell the patient about a known • Always consider pregnancy and lactation side effect until after they experience status that side effect, it is an excuse 1 4/10/17 Reference: Approach to Dermatologic Conditions • Wolverton SE, ed. Acne Comprehensive Infectious diseases of the Skin Dermatologic Drug Eczema nd Therapy, 2 Ed.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Federal Register/Vol. 83, No. 31/Wednesday, February 14, 2018
    Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices 6563 Wireless Telecommunications Bureau Signed: DEPARTMENT OF HEALTH AND and Wireline Competition Bureau (the Dayna C. Brown, HUMAN SERVICES Bureaus) may implement, and (3) certify Secretary and Clerk of the Commission. Centers for Disease Control and its challenge. The USAC system will [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm] validate a challenger’s evidence using Prevention BILLING CODE 6715–01–P an automated challenge validation [CDC–2018–0004; NIOSH–233–B] process. Once all valid challenges have been identified, a challenged party that NIOSH List of Antineoplastic and Other chooses to respond to any valid FEDERAL RESERVE SYSTEM Hazardous Drugs in Healthcare challenge(s) may submit additional data Settings: Proposed Additions to the via the online USAC portal during the Change in Bank Control Notices; NIOSH Hazardous Drug List 2018 established response window. A Acquisitions of Shares of a Bank or AGENCY: Centers for Disease Control and challenged party may submit technical Bank Holding Company information that is probative regarding Prevention, HHS. ACTION: Notice of draft document the validity of a challenger’s speed tests, The notificants listed below have available for public comment. including speed test data and other applied under the Change in Bank device-specific data collected from Control Act (12 U.S.C. 1817(j)) and transmitter monitoring software or, SUMMARY: The National Institute for § 225.41 of the Board’s Regulation Y (12 alternatively, may submit its own speed Occupational Safety and Health test data that conforms to the same CFR 225.41) to acquire shares of a bank (NIOSH) of the Centers for Disease standards and requirements specified by or bank holding company.
    [Show full text]